Misbranding, storage lapses: FDA cancels Cipla Pune unit’s drug licence over Reactin Plus violations
The Maharashtra Food and Drug Administration has revoked Cipla's licenses to sell Reactin Plus Tablets due to serious violations in packaging and storage practices. Medicines were improperly stored on the floor, and the handling of expired products was inadequate. Cipla also failed to comply with the necessary recall protocols for misbranded drugs. The authorities emphasized that stringent measures will be implemented to ensure adherence to drug safety regulations. The Maharashtra Food and Drug Administration has revoked Cipla’s licenses to sell Reactin Plus Tablets due to serious violations in packaging and storage practices. Medicines were improperly stored on the floor, and the handling of expired products was inadequate. Cipla also failed to comply with the necessary recall protocols for misbranded drugs. The authorities emphasized that stringent measures will be implemented to ensure adherence to drug safety regulations.
About the Author
